🔗 Share this article

As the United States proceeds with unprecedented revisions to its vaccination guidelines, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by casting doubt on Covid vaccines in the pandemic and has zeroed in on potential fatalities following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Public health authorities were set to announce major changes to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would put the US out of alignment with many the international standard with insufficient data for public health gain. The announcement has been postponed until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for halting specific childhood vaccine recommendations in the US in order to be more in line with Denmark's approach, a nation with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Expertise

Høeg has no obvious background in drug development, regulation or management, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a major agency. She has no expertise in drug approvals.”

Previous directors of the center would “grasp laws and regulations and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that previous people who led CBER have had.”

The drug center has an enormous portfolio at the FDA, Woodcock emphasized.

“The public just focuses on the novel medication approvals, but the off-patent medication office approves thousands of generic drugs. There’s a biosimilars division, over-the-counter program and more, and every single one have to be supervised,” Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a substantial management component to the job, which supervises more than 5,000 personnel. “It is a massive administrative position, if you perform it correctly,” she concluded.

Response and Controversial Programs

Regarding inquiries about Høeg’s qualifications and whether this selection signifies greater collaboration among FDA leaders on vaccines, a representative stated that the “inquiries are based on flawed premises”.

“Her resume matches the functions of her position,” the representative said, noting the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a disputed expedited medication authorization process that allegedly worried her former heads. “By what process are these drugs being chosen for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

Overall, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed rules of pharmaceuticals, except for immunizations.”

Documented Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if concerning, history, critics have noted. She published a study using non-validated volunteer-provided data to assess the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming federal leadership included changing guidelines for recently developed shots and ending “unnecessary” immunizations, she stated after the election on a online show. At the agency, Dr. Høeg has according to sources floated the idea of preventing adolescent males from obtaining Covid vaccinations.

“She is an complete true believer who starts off with her preconceived notions and tailors the evidence to retrofit the science in a extremely misleading, dishonest fashion,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow skeptics, {like|